Hematology - Oncology Therapy

Have a Promotion Code?

Please enter it here:

Great deals and more!

Sign up for special offers, exclusive discounts, and new product announcements from McGraw-Hill Professional.

SIGN UP TODAY


Date

June 26, 2014

Format

Hardback, 1888 pages

Other Formats


ISBN

0071637893 / 9780071637893

$

Your Price

159.00



Overview


Main description

The Essential Therapy Guide to Cancer, Hematologic Disorders, and Supportive Care--Updated with the Latest Treatment Regimens

More than 500 treatment regimens

Hematology-Oncology Therapy, Second Edition is an up-to-date, comprehensive therapy guide that delivers more than 500 treatment regimens in a succinct, uniform manner. The unique tabular design allows you to instantly locate and implement the proper treatment regimen. Supported by the latest practice guidelines, peer-reviewed literature, and the opinion of experts, Hematology-Oncology Therapy integrates extensive information that is critical to both office- and hospital-based practice of hematology and oncology.

Hematology-Oncology Therapy is divided into three sections:

Oncology:
Provides detailed information about the administration, supportive care, toxicity, dose modification, monitoring, and efficacy of commonly used and recently approved chemotherapeutic regimens, drugs, and biological agents

Supportive Care, Drug Preparation, Complications, and Screening:
Consists of topics commonly encountered in clinical hematology-oncology practice, such as chemotherapy-induced nausea, oncologic emergencies, radiation complications, cancer pain management, cancer screening, and much more

Selected Hematologic Diseases:
Delivers an authoritative guide to therapy for the principal diseases in consultative hematology

This edition of Hematology-Oncology Therapy is enriched by the updating of all chapters as well as the addition of several new chapters; the new "Expert Opinion," which provides recommendations and guidance from experts on the use of treatment regimens; and inclusion of the latest regimens.


Table of contents

Authors
Preface
SECTION I: ONCOLOGY
1. Adrenocortical Cancer, Peter F. Lebowitz and Tito Fojo
2. Anal Cancer, David Ryan and Robert Mayer
3. Biliary Tract Cancer: Gallbladder Cancer and Cholangiocarcinoma, Verena Sagaster and Werner Scheithauer
4. Bladder Cancer, Edwin M. Posadas and William L. Dabut
5. Brain Cancer, Lyndon Kim and Howard Fine
6. Breast Cancer, Peter F. Lebowitz and Jo Anne Zujewski
7. Carcinoid Tumors, Eva Tiensuu Janson and Kjell Oberg
8. Carcinoma of Unknown Primary, David Spigel and F. Anthony Greco
9. Cervical Cancer, Deirdre O'Mahony and Peter Rose
10. Colorectal Cancer, Gregory Leonard and Jean Grem
11. Endometrial Cancer, Deirdre O'Mahoney and Franco Muggia
12. Esophageal Cancer, Gauri Varadhachary and Jaffer Ajani
13. Gastric Cancer, Manish A. Shah, Dana Rathkopf, and Gary K. Schwartz
14. Gestational Trophoblastic Neoplasia, Michael M. Boyiadzis and John Lurain
15. Head and Neck Cancers, Erin Donovan and Barbara Conley
16. Hepatocellular Carcinoma, Joan Maurel and Jordi Bruix
17. HIV-Related Malignancies, Pallavi Kumar and Richard F. Little
18. Leukemia, Acute Lymphoblastic (Adult), Ivan Aksentijevich, Michael M. Boyiadzis, and Judith Karp
19. Leukemia, Acute Myelogenous, Ivan Aksentijevich, Michael M. Boyiadzis, and Judith Karp
20. Leukemia, Chronic Lymphocytic, Salah Abbasi and Bruce D. Cheson
21. Leukemia, Chronic Myelogenous, Michael W.N. Deininger and Brian J. Druker
22. Leukemia, Hairy Cell, Martin S. Tallman
23. Lung Cancer, Enriqueta Felip and Rafael Rosell
24. Lymphoma, Hodgkin, Christina M. Annunziata and Dan L. Longo
25. Lymphoma, Non-Hodgkin, Kieron Dunleavy, David R. Kohler, and Wyndham H. Wilson
26. Melanoma, Michael M. Boyiadzis and Barry Gause
27. Mesothelioma, Verna Vanderpuye and Nicholas J. Vogelzang
28. Multiple Myeloma, Robert Dean and Cynthia E. Dunbar
29. Ovarian Cancer, Eddie Reed
30. Pancreatic Cancer, Michael M. Boyiadzis and Daniel D. Von Hoff
31. Pheochromocytoma, Michael M. Boyiadzis, Karel Pacak, and Tito Fojo
32. Prostate Cancer, Peter F. Lebowitz and William L. Dabut
33. Renal Cell Carcinoma, Michael M. Boyiadzis and Susan Bates
34. Sarcomas, Janice Walshe, Tito Fojo, and Lee Helman
35. Testicular Cancer, Michael M. Boyiadzis and Scott Saxman
36. Thymic Carcinoma, Hanneke Wilmink and Guisseppe Giaconne
37. Thyroid Cancer, Kenneth B. Ain
38. Vaginal Cancer, Thomas Chen and Franco Muggia
SECTION II: SUPPORTIVE CARE, DRUG PREPARATION, COMPLICATIONS, AND SCREENING
39. Chemotherapy-Induced Nausea and Vomiting: Prophylaxis and Treatment, Thomas E. Hughes
40. Drug Preparation and Administration, David R. Kohler
41. Chemotherapy Dose Modifications, Michael Menefee, Pamela W. McDevitt, and Tito Fojo
42. Antineoplastic Drugs: Preventing and Managing Extravasation, David R. Kohler
43. Indications for Growth Factors in the Hemotology-Oncology Setting, Pamela W. McDevitt and James N. Frame
44. Indications for Bisphosphonates in the Hematology-Oncology Setting, Reem A. Shalabi, David R. Kohler, and James N. Frame
45. Transfusion Therapy, Ashok Nambiar and Susan Leitman
46. Oncologic Emergencies, Michael M. Boyiadzis and Tito Fojo
47. Fever and Neutropenia, Juan Gea-Banacloche and Thomas J. Walsh
48. Catheter-Related Bloodstream Infections: Managing and Prevention, Naomi P. O'Grady
49. Venous Catheter-Related Thrombosis, McDonald Horne
50. Complications and Follow-up After Hematopoietic Stem Cell Transplantation (HSCT), Michael M. Boyiadzis, Juan Gea-Banacloche, and Michael R. Bishop
51. Radiation Complications, Diana Stripp and Eli Glatstein
52. Cancer Pain: Assessment and Management, Ann Berger
53. Hospice Care and End-of-Life Issues, Charles F. Von Gunten and David Weismann
54. Cancer Screening, Jennifer Eng-Wong, Kathleen Calzone, and Sheila A. Prindiville
55. Genetics of Common Inherited Cancer Syndromes, Kathleen Calzone, Jennifer Eng-Wong, and Sheila A. Prindiville
SECTION III: SELECTED HEMATOLOGIC DISEASES
56. von Willebrand Disease, Michael M. Boyiadzis and Margaret E. Rick
57. Hemophilia, Steven J. Jubelirer
58. The Hypercoagulable State, Jeffrey I. Zwicker and Kenneth A. Bauer
59. Heparin-Induced Thrombocytopenia (HIT) and HIT with Thromboembolic Syndrome (HITTS), McDonald K. Horne, III
60. Autoimmune Hemolytic Anemia, James N. Frame
61. Sickle Cell Disease: Acute Complications, James N. Frame, Steven J. Jubelirer, and Griffin P. Rodgers
62. Aplastic Anemia, Michael M. Boyiadzis and Neal S. Young
63. Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS), Kiarash Kojouri and James N. George
64. Idiopathic Thrombocytopenic Purpura, Kiarash Kojouri and James N. George
65. Polycythemia Vera, Celia L. Grosskreutz and Steven Fruchtman
66. Essential Thrombocythemia, Celia L. Grosskreutz and Steven Fruchtman
67. Myelodysplastic Syndromes, Michael M. Boyiadzis and Neal S. Young


Author comments

Michael M. Boyiadzis, MD, MHSc
Assistant Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Pittsburgh School of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, PA

James N. Frame, MD, FACP
Clinical Associate Professor
Robert C. Byrd Health Sciences Center of West Virginia University School of Medicine Charleston Division
Medical Director
David Lee Outpatient Cancer Center
Charleston Area Medical Center Health Systems, Inc.
Charleston, WV

David R. Kohler, PharmD
Oncology Clinical Pharmacy Specialist
Bethesda, Maryland

Tito Fojo, MD, PhD
Senior Investigator
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MA





Copyright 2014 McGraw-Hill Global Education Holdings, LLC

WELCOME!

Before you can enjoy free downloads from McGraw-Hill Professional, we ask that you please provide your email address and country.



Yes, I want to receive other special offer.